Comments: A switch from oral (2 mg/day) to transdermal (50 μg/day) 17β-estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with gh deficiency

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 1, 2000, Pages 464-467

  Janssen, Y J H ^a   Helmerhorst, F ^a   Frolich M ^a   Roelfsema, F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DYDROGESTERONE; ESTRADIOL; ESTRADIOL VALERATE; HUMAN GROWTH HORMONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; ESTRONE; GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3;

CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENCY; ESTROGEN THERAPY; ESTRONE BLOOD LEVEL; FEMALE; FLUID RETENTION; GROWTH HORMONE DEFICIENCY; HORMONE BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; ADULT; ARTICLE; BLOOD; BLOOD PRESSURE; BODY COMPOSITION; CLINICAL TRIAL; HEART RATE; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; BLOOD PRESSURE; BODY COMPOSITION; ESTRADIOL; ESTRONE; FEMALE; GROWTH HORMONE; HEART RATE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED;

EID: 0034335394     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.1.464     Document Type: Review

References (21)

1. A low starting dose of genotropin in growth hormone-deficient adults
2. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency
3. Influence of gender on response to growth hormone substitution therapy in adults with growth hormone deficiency
4. The insulin-like growth factor I generation test: Resistance to growth hormone with aging and estrogen replacement therapy
5. An amplitude-specific divergence in the pulsatile mode of GH secretion underlies the gender difference in mean GH concentrations in men and premenopausal women
6. Effects of oral vs. transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: A clinical research center study
7. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women
8. Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: Effect of physiological estrogen replacement
9. Effects of progestin-opposed transdermal estrogen administration on growth hormone and insulin-like growth factor-I in postmenopausal women of different ages
10. Impact of short-term estrogen administration on growth hormone secretion and action: Distinct route-dependent effects on connective and bone tissue metabolism
11. Multi-frequency impedance for the prediction of extracellular water and total body water
12. Using dilution techniques and multifrequency bioelectrical impedance to assess both total body water and extracellular water at baseline and during recombinant human growth hormone (GH) treatment in GH-deficient adults
13. Studies on body composition: Water and chemically combined nitrogen content in relation to fat content
14. Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women
15. Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-I, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels
16. The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin axis: Evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth factors I and II
17. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women-a clinical research center study
18. A dose-ranging trial of a matrix transdermal 17β-estradiol for the prevention of bone loss in early postmenopausal women
19. Comparison of the effects of oral and transdermal oestradiol administration on oestrogen metabolism, protein synthesis, gonadotrophin release, bone turnover and climacteric symptoms in postmenopausal women
20. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): A randomised study
21. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women